PL359108A1 - 7-Hydroksyepiandrosteron o czynności neurochronnej - Google Patents

7-Hydroksyepiandrosteron o czynności neurochronnej

Info

Publication number
PL359108A1
PL359108A1 PL01359108A PL35910801A PL359108A1 PL 359108 A1 PL359108 A1 PL 359108A1 PL 01359108 A PL01359108 A PL 01359108A PL 35910801 A PL35910801 A PL 35910801A PL 359108 A1 PL359108 A1 PL 359108A1
Authority
PL
Poland
Prior art keywords
hydroxyepiandrosterone
neuroprotective activity
hydroxy
steroids
oxo
Prior art date
Application number
PL01359108A
Other languages
English (en)
Other versions
PL200699B1 (pl
Inventor
Ashley Ker Pringle
Lars Eric Sundstrom
Ernst Wülfert
Original Assignee
Hunter-Fleming Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter-Fleming Limited filed Critical Hunter-Fleming Limited
Publication of PL359108A1 publication Critical patent/PL359108A1/pl
Publication of PL200699B1 publication Critical patent/PL200699B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL359108A 2000-06-29 2001-06-29 Zastosowanie 7-hydroksyepiandrosteronu PL200699B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
PCT/GB2001/002937 WO2002000225A1 (en) 2000-06-29 2001-06-29 7-hydroxyepiandrosterone having neuroprotective activity

Publications (2)

Publication Number Publication Date
PL359108A1 true PL359108A1 (pl) 2004-08-23
PL200699B1 PL200699B1 (pl) 2009-01-30

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL359108A PL200699B1 (pl) 2000-06-29 2001-06-29 Zastosowanie 7-hydroksyepiandrosteronu

Country Status (24)

Country Link
US (2) US7718639B2 (pl)
EP (1) EP1294382B1 (pl)
JP (1) JP4942905B2 (pl)
KR (1) KR100786284B1 (pl)
CN (1) CN100459980C (pl)
AT (1) ATE401897T1 (pl)
AU (2) AU6770901A (pl)
CA (1) CA2414584C (pl)
CY (1) CY1108773T1 (pl)
CZ (1) CZ299676B6 (pl)
DE (1) DE60134979D1 (pl)
DK (1) DK1294382T3 (pl)
ES (1) ES2310182T3 (pl)
GB (1) GB2363983A (pl)
HK (1) HK1052300B (pl)
HU (1) HU227152B1 (pl)
IL (2) IL153541A0 (pl)
NO (1) NO327959B1 (pl)
PL (1) PL200699B1 (pl)
PT (1) PT1294382E (pl)
RU (1) RU2307654C2 (pl)
SI (1) SI1294382T1 (pl)
WO (1) WO2002000225A1 (pl)
ZA (1) ZA200300085B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
IN2014DN02014A (pl) 2006-11-21 2015-07-10 Umecrine Ab
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
EP2097079B1 (en) 2006-11-30 2012-06-27 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5707983A (en) * 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
ATE283052T1 (de) 1993-03-09 2004-12-15 Univ Utah Res Found Verwendung von dhea oder dessen derivate zur herstellung eines medikaments zur vorbeugung von progressiver gewebe-nekrose, reperfusionsschädigung, bakterieller translokation und vom atemnotsyndrom bei erwachsenen
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5976850A (en) * 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
ATE284895T1 (de) 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
JP2000511404A (ja) 1996-04-09 2000-09-05 ビー・テイー・ジー・インターナシヨナル・リミテツド 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
FR2760362B1 (fr) * 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
AU747807B2 (en) * 1997-11-24 2002-05-23 Apollo Biopharmaceutics Inc. Testosterone inhibitors and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
JP2003513102A (ja) 1999-11-02 2003-04-08 シエーリング アクチエンゲゼルシャフト 選択的な作用を有するエストロゲンとしての１８−ノル−ステロイド
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
NO20026243D0 (no) 2002-12-27
ES2310182T3 (es) 2009-01-01
US20100173883A1 (en) 2010-07-08
IL153541A0 (en) 2003-07-06
HU227152B1 (en) 2010-08-30
CA2414584C (en) 2009-10-27
PL200699B1 (pl) 2009-01-30
ZA200300085B (en) 2004-04-21
ATE401897T1 (de) 2008-08-15
NO327959B1 (no) 2009-10-26
SI1294382T1 (sl) 2009-02-28
DK1294382T3 (da) 2008-11-24
JP2004501196A (ja) 2004-01-15
EP1294382B1 (en) 2008-07-23
JP4942905B2 (ja) 2012-05-30
RU2307654C2 (ru) 2007-10-10
PT1294382E (pt) 2008-10-21
EP1294382A1 (en) 2003-03-26
HUP0301134A2 (hu) 2003-08-28
RU2003102437A (ru) 2005-01-27
CN1440290A (zh) 2003-09-03
AU6770901A (en) 2002-01-08
HK1052300A1 (en) 2003-09-11
HK1052300B (en) 2009-01-30
US20030166626A1 (en) 2003-09-04
GB0016022D0 (en) 2000-08-23
AU2001267709B2 (en) 2005-07-28
CZ200377A3 (cs) 2003-06-18
CN100459980C (zh) 2009-02-11
US7718639B2 (en) 2010-05-18
DE60134979D1 (de) 2008-09-04
WO2002000225A1 (en) 2002-01-03
CZ299676B6 (cs) 2008-10-15
CY1108773T1 (el) 2014-04-09
CA2414584A1 (en) 2002-01-03
NO20026243L (no) 2003-02-27
KR100786284B1 (ko) 2007-12-18
IL153541A (en) 2008-03-20
HUP0301134A3 (en) 2006-06-28
GB2363983A (en) 2002-01-16
KR20030034113A (ko) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2002246840A1 (en) Extensible and retractable face mask
AU2000259008A1 (en) Flexible circuits with static discharge protection and process for manufacture
AU5326100A (en) Pharmaceutical compositions and methods for use
AU6770501A (en) Neuroprotective 7-beta-hydroxysteroids
AU5601300A (en) Method and compositions for treating and preventing retinal damage
AU3209000A (en) System and method for esd protection
AU6770901A (en) 7-hydroxyepiandrosterone having neuroprotective activity
IL154617A0 (en) Active equipment protection methods and apparatus
AU3068700A (en) Transportation protection device and method for producing the same
AU7130600A (en) Functionally enhanced protective shrink-wrap coverings and methods for their manufacture and use
AU2002223655A1 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
HUP0201478A3 (en) Neuroprotective and retinoprotective ophthalmologic medicines
AU2746100A (en) Broad band controlled angle analog diffuser and associated method
GB2353021B (en) The drug and bug screen
ZA200203312B (en) Vasopressin antagonist formulation and process.
AU1414101A (en) Neuroprotective agents and methods related thereto
AU2002227406A1 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
TW401929U (en) Device for protecting the chair back screen from being excessively raised up and damaged
AU4019100A (en) Dtpa esters with orthogonal removable protecting groups
GB9901767D0 (en) Panel damage protectors
AU1652201A (en) Device for protection of the buttocks and coccyx
HK1043133A (en) Steroid sulfatase inhibitors and methods for making and using the same
AUPS110202A0 (en) Arrangement for software distribution and technical support
TW411074U (en) A quickly combined and movable speaker
HK1051182A (en) Caspase inhibitors and uses thereof

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130629